NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...

Financial analysis of Abbott Laboratories Q4 2024 results and 2025 outlook, with a 'Buy' rating due to revenue growth and EPS ...

When you're buying income stocks, a company's underlying business is arguably still the most crucial factor to consider, even ...

In a report released yesterday, Victoria Lambert from Berenberg Bank maintained a Buy rating on Gerresheimer (0NTI – Research Report), with a ...

The pump-based platform will be a hybrid closed-loop device that will combine an insulin ... division – to develop connected insulin pens. “CGMs provide people with diabetes and their ...

A disposable pen needle is a single-use medical device used for subcutaneous injections, commonly employed in insulin pens for diabetes management. The needle is attached to the pen device, and its ...

Subcutaneous Drug Delivery Devices Market To Reach USD 56.95 Billion By 2032, Growing At A CAGR Of 7.07% - SNS Insider Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and ...

Insulin to treat type 1 diabetes has always been the core of Novo’s business, but the company is once again re-examining how it can expand beyond this base to keep growing revenues and meeting ...

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two ...

Purpose. The efficacy and safety of and key clinical considerations for using U-500 insulin human regular in the treatment of high-dose insulin-treated patients in a wide variety of settings are ...